GUMDROP : Randomized Phase II trial of short-course androgen deprivation therapy with and without bevacizumab for PSA recurrence of prostate cancer after definitive local therapy

Created by Channing Paller, last modified on Apr 14, 2012

Description:

This trial seeks to determine the effect of a short course of androgen deprivation therapy with and without bevacizumab, on relapse-free survival of prostate cancer patients who have undergone definitive local therapy (if post prostatectomy, path stage no greater than T1-3, N1, M0); PSADT<18 months, PSA > 2.0 ng/ml if post primary radiation therapy; prior androgen deprivation therapy allowed if <6 months of treatment and testosterone within 50 units of normal range. 

Link:

http://clinicaltrials.gov/ct2/show/NCT00776594

Site:

Johns Hopkins Hospital

Principal Investigator:

Michael Carducci, M.D.